Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate
Sign Up to like & getrecommendations! Published in 2017 at "mAbs"
DOI: 10.1080/19420862.2017.1305529
Abstract: ABSTRACT MP0250 is a multi-domain drug candidate currently being tested in clinical trials for the treatment of cancer. It comprises one anti-vascular endothelial growth factor-A (VEGF-A), one anti-hepatocyte growth factor (HGF), and two anti-human serum… read more here.
Keywords: mp0250; darpin drug; drug candidate; anti ... See more keywords